Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, non-randomized, open label study of ILX651 in patients with locally
advanced or metastatic non-small cell lung carcinoma (NSCLC). Approximately 60 patients will
be enrolled in this study that is expected to last 18 months. All patients will be treated
with ILX651 administered intravenously (IV) daily for 5 consecutive days once every 21 days.
The primary objective of this study is to determine the overall response rate. The secondary
objectives are to determine the progression free survival, duration of response, time to
tumor progression, survival, safety/tolerability of ILX651, and to evaluate pharmacokinetic
profile.